
Tyra Biosciences, Inc.
Tyra Biosciences, Inc. (TYRA)
WebsitePrice
Market cap
Next catalystExpected 2026Dabogratinib — SURF302, Phase 2 ablative IR NMIBC · Conference presentationCompany source ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PreINDP1P2FilingApproved
Other pipelines
History / paused
PreINDP1P2P3FilingApproved